DelveInsight’s “Diarrhea Pipeline Insight 2026” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in the Diarrhea pipeline landscape. It covers the Diarrhea Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diarrhea Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Diarrhea Pipeline? @ Diarrhea Pipeline Outlook Report

Key Takeaways from the Diarrhea Pipeline Report

• In March 2026, Bausch Health Americas Inc. announced a clinical trial is to learn how rifaximin 200 mg is processed in the body (pharmacokinetics) in children 6 to 11 years old with acute diarrhea that may be caused by bacteria. It will also learn about the safety and effectiveness of rifaximin when given with oral rehydration therapy (ORT) compared with ORT alone.
• In March 2026, GlaxoSmithKline conducted a phase 2 study to evaluate the immune response and safety of a multicomponent, 2-dose Shigella vaccine in preventing shigellosis in African infants. The candidate vaccine, altSonflex1-2-3, is currently being evaluated in a Phase 2 age de-escalation (from the least vulnerable adult population to most vulnerable paediatric population) clinical study in Kenya, with the aim of identifying a preferred dose, using a 3-dose vaccination schedule in infants from 9 months of age (NCT05073003). This Phase 2 clinical study will evaluate the safety and immunogenicity of an alternative 2-dose vaccination schedule.
• DelveInsight’s Diarrhea Pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Diarrhea treatment.
• The leading Diarrhea Companies such as RedHill Biopharma Limited, Puma Biotechnology, Inc., Hunazine Biotech, Vedanta Biosciences, Inc., Crinetics Pharmaceuticals Inc., MGB Biopharma Limited, Daewoong Pharmaceutical Co. LTD., Eveliqure Biotechnologies GmbH, Inmunova S.A., GlaxoSmithKline and others.
• Promising Diarrhea Therapies such as Carbowhite, Nitazoxanide, OPT-80, Racecadotril plus ORS, Rifaximin, Xifaxan®, Elsiglutide and others.

Want to know which companies are leading innovation in Diarrhea? @ Diarrhea Clinical Trials Assessment

The Diarrhea Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Diarrhea Pipeline Report also highlights the unmet needs with respect to the Diarrhea.

Diarrhea Overview

Diarrhea is having three or more loose or liquid stools (poos) in one day, or more frequently than normal. Diarrhea episodes are often caused by a stomach bug (gastroenteritis) and clear up on their own in a few days. However, there are many other causes of diarrhea. Most diarrhea is mild, but it can also be severe even needing admission to hospital. Diarrhea is the augmentation of water content in stools because of an imbalance in the normal functioning of physiologic processes of the small and large intestine responsible for the absorption of various ions, other substrates, and consequently water. Acute diarrhea is described as the acute onset of three or more loose or watery stools a day lasting for 14 days or less.

Diarrhea Emerging Drugs Profile

• VE303: Vedanta Biosciences, Inc.

VE303 is an orally administered, rationally-designed, defined bacterial consortium candidate being developed for high-risk Clostridioides difficile (CDI) infection. VE303 consists of 8 types of clonal human commensal bacteria strains selected for their ability to provide colonization resistance to C. difficile and manufactured under CGMP conditions. Currently, the drug is in clinical trial Phase III stage for the treatment diarrhea disease.

• RHB-102: RedHill Biopharma Limited

RHB-102 is a proprietary, bimodal release, once-daily oral pill formulation of the antiemetic drug ondansetron, targeting several gastrointestinal indications. RHB-102 24 mg is intended to provide patients with relief from nausea and vomiting symptoms for a full 24-hour period with a single oral tablet. Currently, the drug is in clinical trial Phase II stage for the treatment diarrhea disease.

• VR-AD-1005: Hunazine Biotech

VR-AD-1005, a novel antidiarrheal investigational drug for the innovative treatment of severe diarrhea of cholera. VR-AD-1005 is intended to work by reducing the volume of liquid stool produced by the intestine when suffering from the diarrheal pathogen. The drug works within the intestine without affecting its motility and does not induce constipation. Currently, the drug is in Phase II stage of its clinical trial for the treatment of severe diarrhea of cholera.

• ShigETEC: Eveliqure Biotechnologies GmbH

ShigETEC is an orally administered vaccine that induces broad protection against Shigella in a serotype-independent fashion and additionally against ETEC, two major pathogens responsible for diarrhoeal diseases. Based on preclinical data generated by Eveliqure over the last 5 years, it has the potential to be a best-in-class diarrhoea vaccine that targets both travelers and populations in low- and middle-income countries. Currently, the drug is in clinical trial Phase I stage for the treatment of diarrhea disease.

If you’re tracking ongoing Diarrhea Clinical trials, this press release is a must-read @ Diarrhea Treatment Drugs

The Diarrhea Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Diarrhea with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diarrhea Treatment.
• Diarrhea Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Diarrhea Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diarrhea market.

Diarrhea Companies

RedHill Biopharma Limited, Puma Biotechnology, Inc., Hunazine Biotech, Vedanta Biosciences, Inc., Crinetics Pharmaceuticals Inc., MGB Biopharma Limited, Daewoong Pharmaceutical Co. LTD., Eveliqure Biotechnologies GmbH, Inmunova S.A., GlaxoSmithKline and others.

Diarrhea Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Diarrhea Products have been categorized under various Molecule types such as,

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the Diarrhea Pipeline Report covers it all @ Diarrhea Market Drivers and Barriers, and Future Perspectives

Scope of the Diarrhea Pipeline Report

• Coverage- Global
• Diarrhea Companies- RedHill Biopharma Limited, Puma Biotechnology, Inc., Hunazine Biotech, Vedanta Biosciences, Inc., Crinetics Pharmaceuticals Inc., MGB Biopharma Limited, Daewoong Pharmaceutical Co. LTD., Eveliqure Biotechnologies GmbH, Inmunova S.A., GlaxoSmithKline and others.
• Diarrhea Therapies- Carbowhite, Nitazoxanide, OPT-80, Racecadotril plus ORS, Rifaximin, Xifaxan®, Elsiglutide and others.
• Diarrhea Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Diarrhea Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Diarrhea Treatment landscape in this detailed analysis @ Diarrhea Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Diarrhea: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Diarrhea – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. VE303: Vedanta Biosciences, Inc.
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. VR-AD-1005: Hunazine Biotech
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ShigETEC: Eveliqure Biotechnologies GmbH
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Diarrhea Key Companies
21. Diarrhea Key Products
22. Diarrhea – Unmet Needs
23. Diarrhea – Market Drivers and Barriers
24. Diarrhea – Future Perspectives and Conclusion
25. Diarrhea Analyst Views
26. Diarrhea Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/diarrhea-pipeline-insight